A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazolesMuhamad Mustafa(Deraya University), Gamal El‐Din A. Abuo‐Rahma(Deraya University)European Journal of Medicinal ChemistryMay 29, 202110.1016/j.ejmech.2021.113569Cited by 41SaveCiteExport RISWatch citationsRelated PapersCoronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview|Vaccines|2021|45